comparemela.com

Latest Breaking News On - ஒப்புதல் ப்ரோக்ர்யாம் - Page 11 : comparemela.com

TCDA INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Tricida Inc

TCDA INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Tricida Inc
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

Share this article Share this article TOKYO and BOTHELL, Wash., Feb. 12, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) and Seagen Inc. (Nasdaq: SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV ® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. At the time of pre-specified interim analysis, patients who received PADCEV in the trial lived a median of 3.9 months longer than those who received chemotherapy. Median overall survival was 12.9 vs. 9.0 months, respectively (HR=0.70 [95 percent Confidence Interval (CI): 0.56-0.89], p=0.001). For patients in the PADCEV arm of the trial, maculopapular rash, fatigue and decreased neutrophil count were the most frequent Grade 3 or greater treatment-related adverse events (TRAEs) occurring in more tha

Bragar Eagel & Squire, P C Reminds Investors That Class Action Lawsuits Have Been Filed Against CD Projekt, SolarWinds, QuantumScape, and Tricida and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CD Projekt, SolarWinds, QuantumScape, and Tricida and Encourages Investors to Contact the Firm February 10, 2021 19:16 ET | Source: Bragar Eagel & Squire Bragar Eagel & Squire New York, New York, UNITED STATES NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CD Projekt S.A. (Other OTC: OTGLY, OTGLF), SolarWinds Corporation (NYSE: SWI), QuantumScape Corporation (NYSE: QS), and Tricida, Inc. (NASDAQ: TCDA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tricida, Inc of Class Action Lawsuit and Upcoming Deadline

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tricida, Inc of Class Action Lawsuit and Upcoming Deadline

(2) NEW YORK, Jan. 31, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Tricida, Inc. ( Tricida or the Company ) (NASDAQ: TCDA) and certain of its officers. The class action, filed in United States District Court for the Northern District of California, and docketed under 21-cv-00076, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tricida securities between September 4, 2019 and October 28, 2020, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.